Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Minimal Residual Disease

Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia

Leukemia volume 19, pages 1416–1423 (2005)Cite this article

Abstract

In search for general PCR targets for minimal residual disease (MRD) studies in acute myeloid leukemia (AML), Wilms' tumor gene 1 (WT1) expression was assessed by real-time RT-PCR relative to the control gene ABL in 569 archived samples of AML patients (pts). Pts were analyzed at diagnosis (n=116) and during follow-up (n=105, median 4 times, range 2–17). Median follow-up time was 258 days (range 16–1578 days). In 66 pts, the WT1 expression was analyzed in comparison to a second PCR marker or to multiparameter flow cytometry. Quantitative WT1 levels correlated to the clinical course or a second marker in 83–96% of the cases. Prognostic significance of WT1 levels was analyzed at diagnosis and three intervals: (1) days 16–60, (2) days 61–120, and (3) days 121–180 after start of chemotherapy. Higher levels of WT1 expression were associated with shorter overall survival (OS) and event-free survival (EFS) within intervals 2 and 3 but not at diagnosis or interval 1. In addition, within these intervals, WT1/ABL levels ⩽0.4% were associated with improved OS and EFS. An increase of WT1 levels was detected in 16/44 cases, which subsequently relapsed within a median of 38 days (range 8–180 days). In conclusion, quantification of WT1 may be used for MRD studies and for prognostification in AML.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W . New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003; 102: 2746–2755.

    Article  CAS  Google Scholar 

  2. Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002; 99: 443–449.

    Article  CAS  Google Scholar 

  3. Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 2002; 16: 1176–1181.

    Article  CAS  Google Scholar 

  4. Cilloni D, Saglio G . WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 2004; 112: 79–84.

    Article  CAS  Google Scholar 

  5. Call KM, Glaser T, Ito CY, Buckler A, Pelletier J, Haber DA et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509–520.

    Article  CAS  Google Scholar 

  6. Cook DM, Hinkes MT, Bernfield M, Rauscher III FJ . Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene 1996; 13: 1789–1799.

    CAS  PubMed  Google Scholar 

  7. Englert C, Hou X, Maheswaran S, Bennett P, Ngwu C, Re GG et al. WT1 suppress synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995; 14: 4662–4675.

    Article  CAS  Google Scholar 

  8. Miwa H, Beran M, Saunders GF . Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405–409.

    CAS  PubMed  Google Scholar 

  9. Miyagi T, Ahuja H, Kubonishi I, Koeffler HP, Miyoshi I . Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia 1993; 7: 970–977.

    CAS  PubMed  Google Scholar 

  10. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89: 1405–1412.

    CAS  PubMed  Google Scholar 

  11. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwaz S et al. Presence of Wilms tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060–1067.

    CAS  PubMed  Google Scholar 

  12. Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ . A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines. Oncogene 1996; 12: 1005–1014.

    CAS  PubMed  Google Scholar 

  13. Deuel TF, Guan LS, Wang ZY . Wilms' tumor gene product WT1 arrests macrophage differentiation of HL60 cells through its zinc-finger domain. Biochem Biophys Res Commun 1999; 254: 192–196.

    Article  CAS  Google Scholar 

  14. Smith SI, Weil D, Johnson GR, Boyd AW, Li CL . Expression of the Wilms' tumor suppressor gene, WT1 is upregulated by leukemia inhibitory factor and induces monocytic differentiation in M1 leukemic cells. Blood 1998; 91: 764–773.

    CAS  PubMed  Google Scholar 

  15. Svedberg H, Chylicki K, Baldetorp B, Rauscher III FL, Gullberg U . Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks part of the differentiation program. Oncogene 1998; 16: 925–932.

    Article  CAS  Google Scholar 

  16. Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L . The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 1997; 25: 945–950.

    CAS  PubMed  Google Scholar 

  17. Menssen HD, Renkl HJ, Entezami M, Thiel E . Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. Blood 1997; 89: 3486–3487.

    CAS  PubMed  Google Scholar 

  18. Sekiya M, Adachi M, Hinoda Y, Imai K, Yachi A . Downregulation of the Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells. Blood 1994; 83: 1876–1882.

    CAS  PubMed  Google Scholar 

  19. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115–2121.

    Article  CAS  Google Scholar 

  20. Trka J, Kalinova M, Hrusak O, Zuna J, Krejci O, Madzo J et al. Real time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002; 16: 1381–1389.

    Article  CAS  Google Scholar 

  21. Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P . WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single-centre study. Br J Haematol 2004; 125: 590–600.

    Article  CAS  Google Scholar 

  22. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698–1704.

    Article  CAS  Google Scholar 

  23. Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996; 88: 2267–2278.

    CAS  PubMed  Google Scholar 

  24. Bergmann L, Maurer U, Weidmann E . Wilms tumor gene expression in acute myeloid leukemias. Leuk Lymphoma 1997; 25: 435–443.

    Article  CAS  Google Scholar 

  25. Garg M, Moore H, Tobal K, Liu Yin JA . Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 2003; 123: 49–59.

    Article  CAS  Google Scholar 

  26. Gaiger A, Schmid D, Heinze G, Linnerth B, Greinix H, Halhs P et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998; 12: 1886–1894.

    Article  CAS  Google Scholar 

  27. Schmid D, Heinze G, Linnerth B . Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997; 11: 639–643.

    Article  CAS  Google Scholar 

  28. Inoue K, Sugiyama H, Ogawa, Nakagawa M, Yamagami T, Miwa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071–3079.

    CAS  PubMed  Google Scholar 

  29. Bergmann L, Mieting C, Maurer U, Brieger J, Karakas T, Weidmann E et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long term outcome. Blood 1997; 90: 1217–1225.

    CAS  PubMed  Google Scholar 

  30. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. French–American–British (FAB) co-operative group. Br J Haematol 1976; 33: 451–458.

    Article  CAS  Google Scholar 

  31. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991; 78: 325–329.

    Article  CAS  Google Scholar 

  32. Jaffe ES, Harris NL, Stein H, Vardiman JW . World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001.

    Google Scholar 

  33. Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93: 4116–4124.

    CAS  PubMed  Google Scholar 

  34. Buchner T, Hiddemann W, Berdel WE, Wormann B, Schoch C, Fonatsch C, et al, German AML Cooperative Group. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD–HAM–TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003; 21: 4496–5004.

    Article  Google Scholar 

  35. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.

    Article  CAS  Google Scholar 

  36. Schnittger S, Schoch C, Kern W, Hiddemann W, Haferlach T . FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematol 2004; 112: 68–78.

    Article  CAS  Google Scholar 

  37. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T . Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104: 3078–3085.

    Article  CAS  Google Scholar 

  38. Kreuzer KA, Saborowski A, Lupberger J, Appelt C, Na IK, Le Coutre P et al. Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukemias. Br J Haematol 2001; 114: 313–318.

    Article  CAS  Google Scholar 

  39. Elmaagacli AH, Beelen DW, Trenschel R, Schaefer UW . The detection of WT1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 2000; 25: 91–96.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Department III, Laboratory for Leukemia Diagnostics, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany

    M Weisser, W Kern, S Rauhut, C Schoch, W Hiddemann, T Haferlach & S Schnittger

Authors
  1. M Weisser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W Kern
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Rauhut
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Schoch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Haferlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Schnittger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Weisser.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weisser, M., Kern, W., Rauhut, S. et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19, 1416–1423 (2005). https://doi.org/10.1038/sj.leu.2403809

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403809

Keywords

This article is cited by

Search

Advanced search

Quick links